Table 3. Individual treatment-emergent adverse events (TEAEs) during oral immunotherapy (OIT).
| No. | M/F | AEs | Severity (grade) | Days of OIT | Duration (days) | |
|---|---|---|---|---|---|---|
| OIT group | 1 | M | Rhinorrhea | Grade 1 | 0 | 1 |
| 2 | F | Diarrhea | Grade 1 | 5 | 1 | |
| 3 | F | Abdominal pain | Grade 1 | 0 | 0.5 | |
| Abdominal pain | Grade 1 | 2 | 3 | |||
| 4 | F | Stomach pain | Grade 1 | 0 | 3 | |
| Bloating | Grade 1 | 6 | 1 | |||
| Stomach pain | Grade 1 | 41 | 1 | |||
| 5 | F | Abdominal discomfort | Grade 1 | 0 | 26 | |
| 6 | F | Stomach pain | Grade 1 | 25 | 2 | |
| Placebo | 1 | F | Watering eyes | Grade 1 | 0 | 1 |
| 2 | F | Oral dysesthesia | Grade 1 | 13 | 6 | |
| Abdominal pain | Grade 1 | 34 | 6 | |||
| 3 | F | Chest discomfort | Grade 1 | 0 | 0.1 | |
| Laryngopharyngeal dysesthesia | Grade 1 | 0 | 0.04 | |||
| 4 | F | Loose stools | Grade 1 | 17 | 46 | |
| 5 | F | Abdominal pain | Grade 1 | 19 | 3 |
AEs were graded according to Common Terminology Criteria for Adverse Event (CTCAE) v4.0/MedDRA v12.0. M, male; F, female.